Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338764 | 0.77 | MEN1 (0.31) | — | |
| SCHEMBL2638146 | 0.76 | KDM4E (0.31) | — | |
| SCHEMBL3339097 | 0.76 | KDM4E (0.30) | — | |
| SCHEMBL3340932 | 0.75 | PDE4D (0.32) | MAPT | |
| SCHEMBL3337860 | 0.74 | DPP4 (0.37) | MAPT | |
| SCHEMBL3367417 | 0.72 | L3MBTL1 (0.34) | MAPT | |
| SCHEMBL3338639 | 0.72 | PDE10A (0.33) | — | |
| SCHEMBL3344737 | 0.71 | FYN (0.30) | — | |
| SCHEMBL3367399 | 0.68 | TRPV1 (0.30) | — | |
| SCHEMBL3344951 | 0.68 | ALDH1A1 (0.40) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | claimed |
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152205-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | MAPT 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.